Solving Dysbiosis of the Newborn Gut Microbiome

Infinant Health (formerly Evolve BioSystems) manufactures Evivo®, a proprietary groundbreaking probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency, and is a fully commercialized consumer product.


Infinant Health, formerly Evolve BioSystems is the manufacturer of Evivo®, a groundbreaking probiotic proven to resolve infant gut dysbiosis, also know as Newborn Gut Deficiency (NGD). Evivo supplies activated B. infantis (EVC001), which studies have shown guides the critical development of infants’ digestive and immune systems. By restoring this missing bacterium to the infant gut microbiome, Evivo helps reduce potentially pathogenic bacteria by 80% while simultaneously reducing intestinal inflammation. This reduction in harmful pathogens helps reduce the risk of both short- and long-term health issues, including colic, diaper rash, eczema, asthma, allergies and type 1 diabetes.

Infinant Health is a spin off from the Foods for Health Institute (FFHI) at the University of California, Davis, and incorporates more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Evolve is a portfolio company of Manna Tree Partners, Cargill, the Bill & Melinda Gates Foundation and Horizons Ventures.

Evivo Product

Careers at Infinant Health

Interested in current openings? Visit our Infinant Health careers section to see if there is an opportunity that is a fit for your expertise, please reach out.